Dose and duration of IL-2 therapy
Patient no. . | Diagnosis . | Age, y . | IL-2 dose, U/m2 per d . | Duration of IL-2 therapy when tested, wk . | After IL-2 testing, wk . |
|---|---|---|---|---|---|
| 1 | Renal cell carcinoma | 66 | 1 × 106 | 9 | NA |
| 2 | Renal cell carcinoma | 42 | 3-6 × 105 | 10 | NA |
| 3 | Renal cell carcinoma | 53 | 1-1.5 × 106 | 10 | NA |
| 4 | Renal cell carcinoma | 56 | 6 × 105 | 11 | NA |
| 5 | Renal cell carcinoma | 58 | 6 × 105 | 8 | NA |
| 6 | Lung sarcoma | 23 | 1.5 × 105 | 8 | NA |
| 7 | Renal cell carcinoma | 67 | 1-1.5 × 106 | 10 | 19 |
| 8 | Rectal cancer | 42 | 6 × 105 | 8 | NA |
| 9 | NSCL carcinoma | 31 | 6 × 105 | 6.5 | 45 |
| 10 | Colon cancer | 62 | 6 × 105 | 10 | NA |
| 11 | Renal cell carcinoma | 60 | 0.6-1.25 × 106 | 9 | 17 |
| 12 | Melanoma | 41 | 4.5-6 × 105 | 10 | 19 |
| 13 | CML (chronic phase) | 38 | 2-4 × 105 | 11 | 19.5 |
| 14 | CML (chronic phase) | 44 | 4 × 105 | 4 | 17 |
| 15 | CML (chronic phase) | 44 | 2-4 × 105 | 4 | NA |
| 16 | CML (chronic phase) | 49 | 2-4 × 105 | 9 | 20 |
| 17 | CML (chronic phase) | 41 | 3-4 × 105 | 5 | NA |
| 18 | CML (accelerated phase) | 24 | 4 × 105 | 5 | 38 |
| 19 | CML (chronic phase) | 33 | 2-4 × 105 | 4 | NA |
| 20 | CML (chronic phase) | 49 | 2-4 × 105 | 5 | 17 |
| 21 | CML (chronic phase) | 29 | 2-4 × 105 | 5.5 | 21 |
Patient no. . | Diagnosis . | Age, y . | IL-2 dose, U/m2 per d . | Duration of IL-2 therapy when tested, wk . | After IL-2 testing, wk . |
|---|---|---|---|---|---|
| 1 | Renal cell carcinoma | 66 | 1 × 106 | 9 | NA |
| 2 | Renal cell carcinoma | 42 | 3-6 × 105 | 10 | NA |
| 3 | Renal cell carcinoma | 53 | 1-1.5 × 106 | 10 | NA |
| 4 | Renal cell carcinoma | 56 | 6 × 105 | 11 | NA |
| 5 | Renal cell carcinoma | 58 | 6 × 105 | 8 | NA |
| 6 | Lung sarcoma | 23 | 1.5 × 105 | 8 | NA |
| 7 | Renal cell carcinoma | 67 | 1-1.5 × 106 | 10 | 19 |
| 8 | Rectal cancer | 42 | 6 × 105 | 8 | NA |
| 9 | NSCL carcinoma | 31 | 6 × 105 | 6.5 | 45 |
| 10 | Colon cancer | 62 | 6 × 105 | 10 | NA |
| 11 | Renal cell carcinoma | 60 | 0.6-1.25 × 106 | 9 | 17 |
| 12 | Melanoma | 41 | 4.5-6 × 105 | 10 | 19 |
| 13 | CML (chronic phase) | 38 | 2-4 × 105 | 11 | 19.5 |
| 14 | CML (chronic phase) | 44 | 4 × 105 | 4 | 17 |
| 15 | CML (chronic phase) | 44 | 2-4 × 105 | 4 | NA |
| 16 | CML (chronic phase) | 49 | 2-4 × 105 | 9 | 20 |
| 17 | CML (chronic phase) | 41 | 3-4 × 105 | 5 | NA |
| 18 | CML (accelerated phase) | 24 | 4 × 105 | 5 | 38 |
| 19 | CML (chronic phase) | 33 | 2-4 × 105 | 4 | NA |
| 20 | CML (chronic phase) | 49 | 2-4 × 105 | 5 | 17 |
| 21 | CML (chronic phase) | 29 | 2-4 × 105 | 5.5 | 21 |
NA indicates not applicable